SynthesisEpidemiology and infection2020
Epidemiological study of
Synthesis in Epidemiology and infection, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Complementary and Alternative Therapies for Onychomycosis: A Systematic Review of the Clinical Evidence.Skin appendage disorders · 2022Pooled it
- Trichosporon ocular infections: Genotyping, antifungal susceptibility, clinico-microbiological correlation, and literature review.Indian journal of ophthalmology · 2026Review
- Lessons Learned from a Nosocomial Outbreak ofJournal of fungi (Basel, Switzerland) · 2026Article
- Trichosporon fungemia in critically ill patients: A case series.Journal of postgraduate medicine · 2026Article
- Trichosporon asahii subcutaneous soft tissue infection after trauma surgery in an immunocompetent patient: a case report.BMC infectious diseases · 2026Article
- Catheter-AssociatedJournal of fungi (Basel, Switzerland) · 2026Article
- Comparison of two MALDI-TOF MS platforms for identification of Trichosporon isolates from patients in a tertiary hospital in Hefei, China.BMC infectious diseases · 2026Article
- Article
- In Silico Analysis and Expression Profiling of Adhesin-Like Flocculins in Trichosporon asahii.Mycopathologia · 2026Article
- Clinical Manifestations of Emerging Trichosporon spp. Infections, France.Emerging infectious diseases · 2026Article
- Ferrous sulfate induces ferroptosis-like cell death inFrontiers in microbiology · 2026Article
- From the Petri dish to the patient's bedside: interpretingFrontiers in immunology · 2026Article
- Cryptococcal antigen cross-reactivity is associated with fatal trichosporonosis in patients with hematologic diseases.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Invasive trichosporonosis in children: a 10-year experience from a tertiary care center in Türkiye.Journal of tropical pediatrics · 2025Article
- Detection of Multiple Nosocomial Trichosporon asahii Transmission Events via Microsatellite Typing Assay, South America.Emerging infectious diseases · 2025Article
- Biocide Tolerance, Biofilm Formation, and Efflux Pump Activity in Clinical Isolates ofInfectious disease reports · 2025Article
- Investigation of voriconazole heteroresistance in clinical isolates ofMicrobiology spectrum · 2025Article
- Article
- A Review of Case Reports of Rare Clinical Yeast Infections in the Last Five Years.Mycopathologia · 2025Review
- Identification of the ADH gene family in Trichosporon asahii and the role of TaADH_like in pathogenicity and fluconazole resistance.BMC genomics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trichosporon is a yeast-like basidiomycete, a conditional pathogenic fungus that is rare in the clinic but often causes fatal infections in immunocompromised individuals. Trichosporon asahii is the most common pathogenic fungus in this genus and the occurrence of infections has dramatically increased in recent years. Here, we report a systematic literature review detailing 140 cases of T. asahii infection reported during the past 23 years. Statistical analysis shows that T. asahii infections were most frequently reported within immunodeficient or immunocompromised patients commonly with blood diseases. Antibiotic use, invasive medical equipment and chemotherapy were the leading risk factors for acquiring infection. In vitro susceptibility, clinical information and prognosis analysis showed that voriconazole is the primary drug of choice in the treatment of T. asahii infection. Combination treatment with voriconazole and amphotericin B did not show superiority over either drug alone. Finally, we found that the types of infections prevalent in China are significantly different from those in other countries. These results provide detailed information and relevant clinical treatment strategies for the diagnosis and treatment of T. asahii infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.